JP Morgan Chase
ICPT

JP Morgan Chase’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

JP Morgan Chase’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-289,771
Closed -$5.37M – 8062
2023
Q3 		$5.37M Buy
289,771
+259,999
+873% +$2.94M ﹤0.01% 2780
2023
Q2 		$329K Sell
29,772
-165,696
-85% -$2.31M ﹤0.01% 4758
2023
Q1 		$2.63M Sell
195,468
-201,335
-51% -$3.48M ﹤0.01% 3346
2022
Q4 		$4.91M Buy
396,803
+222,952
+128% +$3.16M ﹤0.01% 2828
2022
Q3 		$2.42M Sell
173,851
-151,129
-47% -$2.43M ﹤0.01% 3317
2022
Q2 		$4.49M Buy
324,980
+19,539
+6% +$313K ﹤0.01% 2865
2022
Q1 		$4.97M Buy
305,441
+121,955
+66% +$1.91M ﹤0.01% 3007
2021
Q4 		$2.99M Sell
183,486
-14,826
-7% -$250K ﹤0.01% 3498
2021
Q3 		$2.94M Sell
198,312
-910,543
-82% -$14.6M ﹤0.01% 3469
2021
Q2 		$22.1M Buy
1,108,855
+143,504
+15% +$2.84M ﹤0.01% 1754
2021
Q1 		$22.3M Sell
965,351
-352,864
-27% -$9.84M ﹤0.01% 1666
2020
Q4 		$32.6M Buy
1,318,215
+63,665
+5% +$2.11M ﹤0.01% 1298
2020
Q3 		$52.4M Sell
1,254,550
-324,052
-21% -$14.9M 0.01% 950
2020
Q2 		$75.6M Buy
1,578,602
+109,259
+7% +$8.44M 0.01% 742
2020
Q1 		$92.5M Sell
1,469,343
-55,070
-4% -$4.95M 0.02% 588
2019
Q4 		$189M Buy
1,524,413
+59,935
+4% +$5.37M 0.04% 450
2019
Q3 		$97.2M Buy
1,464,478
+178,786
+14% +$12M 0.02% 677
2019
Q2 		$102M Buy
1,285,692
+536,707
+72% +$48M 0.02% 664
2019
Q1 		$83.8M Sell
748,985
-494,986
-40% -$54.1M 0.02% 717
2018
Q4 		$125M Buy
1,243,971
+46,929
+4% +$4.86M 0.03% 550
2018
Q3 		$151M Sell
1,197,042
-75,239
-6% -$7.96M 0.03% 542
2018
Q2 		$107M Sell
1,272,281
-366,894
-22% -$26.9M 0.02% 637
2018
Q1 		$101M Sell
1,639,175
-293,559
-15% -$17.7M 0.02% 627
2017
Q4 		$113M Buy
1,932,734
+1,041,161
+117% +$65.7M 0.02% 598
2017
Q3 		$51.4M Buy
891,573
+388,035
+77% +$41.8M 0.01% 915
2017
Q2 		$61M Sell
503,538
-363,227
-42% -$42.1M 0.01% 820
2017
Q1 		$98M Buy
866,765
+19,752
+2% +$2.31M 0.02% 637
2016
Q4 		$92M Buy
847,013
+12,960
+2% +$1.54M 0.02% 620
2016
Q3 		$137M Buy
834,053
+4,615
+0.6% +$728K 0.03% 466
2016
Q2 		$118M Buy
829,438
+501,324
+153% +$73.1M 0.03% 515
2016
Q1 		$42.2M Buy
328,114
+12,117
+4% +$1.43M 0.01% 901
2015
Q4 		$47.2M Buy
315,997
+10,569
+3% +$1.79M 0.01% 827
2015
Q3 		$50.7M Buy
305,428
+13,754
+5% +$3.03M 0.01% 776
2015
Q2 		$70.4M Buy
291,674
+17,108
+6% +$4.56M 0.02% 744
2015
Q1 		$77.4M Buy
274,566
+219,749
+401% +$47.6M 0.02% 716
2014
Q4 		$8.55M Buy
54,817
+39,245
+252% +$7.25M ﹤0.01% 2058
2014
Q3 		$3.69M Buy
15,572
+5,515
+55% +$1.41M ﹤0.01% 2552
2014
Q2 		$2.38M Sell
10,057
-38,780
-79% -$10.2M ﹤0.01% 2430
2014
Q1 		$16.1M Buy
+48,837
New +$16.5M ﹤0.01% 1462
2013
Q3 		– Sell
-106,209
Closed -$4.76M – 4481
2013
Q2 		$4.76M Buy
+106,209
New +$3.63M ﹤0.01% 2171

JP Morgan Chase's ICPT Position: Q4 2023 in Review

JP Morgan Chase sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2023, closing a stake of 289,771 shares — an estimated $5.37M sold.

JP Morgan Chase first reported a position in ICPT in Q2 2013 and held it in 40 quarters. The position peaked at $189M in Q4 2019. 0 funds tracked by Wall St. Rank hold ICPT as of Q4 2023.

  • JP Morgan Chase reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
  • JP Morgan Chase sold 289,771 Intercept Pharmaceuticals, Inc. shares in Q4 2023, an estimated $5.37M.
  • JP Morgan Chase first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2013 and held it in 40 quarters.
  • JP Morgan Chase's Intercept Pharmaceuticals, Inc. position peaked at $189M in Q4 2019.
  • 0 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2023.

Based on JP Morgan Chase's 13F filing for Q4 2023, filed 12 Feb 2024.